Literature DB >> 25482616

Potential role of High mobility group box 1 in hepatocellular carcinoma.

Rong-Rong Zhou1, Xu-Yuan Kuang, Yan Huang, Ning Li, Ming-Xiang Zou, Dao-Lin Tang, Xue-Gong Fan.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is characterized as a typical inflammation-related carcinoma. High mobility group box protein 1 (HMGB1), a non-histone DNA-binding protein, is identified as a potent proinflammatory mediator when presents extracellularly. Recently, a growing body of evidence indicates that HMGB1 plays a potential role in HCC, but many questions remain unanswered about the relationship between HMGB1 and HCC formation and development. This review focuses on the biological effect of HMGB1, and discusses the association of HMGB1 with HCC and potential use of strategies targeting HMGB1 in HCC treatment.

Entities:  

Keywords:  biological effect; chronic hepatitis; hepatocellular carcinoma; high mobility group box protein 1; tumor microenvironment

Mesh：

Substances：

Year:  2014        PMID： 25482616      PMCID： PMC4594547          DOI： 10.4161/19336918.2014.969139

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN： 1933-6918            Impact factor:   3.405


  61 in total

Review 1.  HMG1 and 2, and related 'architectural' DNA-binding proteins.

Authors:  J O Thomas; A A Travers
Journal:  Trends Biochem Sci       Date:  2001-03       Impact factor: 13.807

2.  HMG-1 as a late mediator of endotoxin lethality in mice.

Authors:  H Wang; O Bloom; M Zhang; J M Vishnubhakat; M Ombrellino; J Che; A Frazier; H Yang; S Ivanova; L Borovikova; K R Manogue; E Faist; E Abraham; J Andersson; U Andersson; P E Molina; N N Abumrad; A Sama; K J Tracey
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

3.  A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release.

Authors:  Huan Yang; Hulda S Hreggvidsdottir; Karin Palmblad; Haichao Wang; Mahendar Ochani; Jianhua Li; Ben Lu; Sangeeta Chavan; Mauricio Rosas-Ballina; Yousef Al-Abed; Shizuo Akira; Angelika Bierhaus; Helena Erlandsson-Harris; Ulf Andersson; Kevin J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

4.  Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus.

Authors:  Dara Ditsworth; Wei-Xing Zong; Craig B Thompson
Journal:  J Biol Chem       Date:  2007-04-12       Impact factor: 5.157

5.  Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer.

Authors:  Hidenori Akaike; Koji Kono; Hidemitsu Sugai; Akihiro Takahashi; Kousaku Mimura; Yoshihiko Kawaguchi; Hideki Fujii
Journal:  Anticancer Res       Date:  2007 Jan-Feb       Impact factor: 2.480

6.  The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo.

Authors:  Francesca Riuzzi; Guglielmo Sorci; Rosario Donato
Journal:  J Biol Chem       Date:  2006-01-09       Impact factor: 5.157

7.  HMGB-1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion.

Authors:  Davide Agnello; Haichao Wang; Huan Yang; Kevin J Tracey; Pietro Ghezzi
Journal:  Cytokine       Date:  2002-05-21       Impact factor: 3.861

8.  Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation.

Authors:  Luis Ulloa; Mahendar Ochani; Huan Yang; Mahira Tanovic; Daniel Halperin; Runkuan Yang; Christopher J Czura; Mitchell P Fink; Kevin J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-03       Impact factor: 11.205

Review 9.  The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Alfredo Criollo; Carla Ortiz; Rosette Lidereau; Christophe Mariette; Nathalie Chaput; Jean-Paul Mira; Suzette Delaloge; Fabrice André; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Immunol Rev       Date:  2007-12       Impact factor: 12.988

Review 10.  Cytokine inhibition of JAK-STAT signaling: a new mechanism of growth hormone resistance.

Authors:  Charles H Lang; Ly Hong-Brown; Robert A Frost
Journal:  Pediatr Nephrol       Date:  2004-11-10       Impact factor: 3.714
View more
  9 in total

1.  VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.

Authors:  Zhangya Pu; Dan G Duda; Yuanyuan Zhu; Siya Pei; Xiaofang Wang; Yan Huang; Panpan Yi; Zebing Huang; Fang Peng; Xingwang Hu; Xuegong Fan
Journal:  J Transl Med       Date:  2022-05-13       Impact factor: 8.440

Review 2.  The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications.

Authors:  Lei Wu; Lili Yang
Journal:  Oncol Lett       Date:  2018-03-08       Impact factor: 2.967

Review 3.  MicroRNA-Mediated Regulation of HMGB1 in Human Hepatocellular Carcinoma.

Authors:  Jianing Yan; Shibo Ying; Xiujun Cai
Journal:  Biomed Res Int       Date:  2018-01-31       Impact factor: 3.411

4.  Systematic Review and Meta-Analysis on the Association between Polymorphisms in Genes of IL-12 Signaling Pathway and Hepatocellular Carcinoma Risk.

Authors:  Yao Xiao; Guodong Liu; Liansheng Gong
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

Review 5.  HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma.

Authors:  Yanbin Wang; Zhaoqiang Jiang; Jianing Yan; Shibo Ying
Journal:  Dis Markers       Date:  2019-02-12       Impact factor: 3.434

6.  microRNA-548b suppresses aggressive phenotypes of hepatocellular carcinoma by directly targeting high-mobility group box 1 mRNA.

Authors:  Zhennan Yun; Fanqi Meng; Peiqiang Jiang; Meng Yue; Shiquan Li
Journal:  Cancer Manag Res       Date:  2019-06-25       Impact factor: 3.989

7.  Ablation of high-mobility group box-1 in the liver reduces hepatocellular carcinoma but causes hyperbilirubinemia in Hippo signaling-deficient mice.

Authors:  Dipti Athavale; Zhuolun Song; Romain Desert; Hui Han; Sukanta Das; Xiaodong Ge; Sai Santosh Babu Komakula; Wei Chen; Shenglan Gao; Daniel Lantvit; Grace Guzman; Natalia Nieto
Journal:  Hepatol Commun       Date:  2022-03-28

8.  High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.

Authors:  Yinzong Xiao; Lunquan Sun; Yongming Fu; Yan Huang; Rongrong Zhou; Xingwang Hu; Pengcheng Zhou; Jun Quan; Ning Li; Xue-Gong Fan
Journal:  BMC Cancer       Date:  2017-12-15       Impact factor: 4.430

9.  Antitumor Activity of the Chinese Medicine JC-001 Is Mediated by Immunomodulation in a Murine Model of Hepatocellular Carcinoma.

Authors:  Meng-Hsien Chuang; Jinghua Tsai Chang; Li-Jin Hsu; Ming-Shiou Jan; Fung-Jou Lu
Journal:  Integr Cancer Ther       Date:  2016-10-03       Impact factor: 3.279
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.